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Abstract
Recent data have established the HIV-1 and SIV escape CTL through epitope mutation. However,
three novel studies prove that such escape comes at a "cost" to overall viral fitness. Understanding
how HIV-1/SIV escape CTL and the impact of the escape mutations has tremendous importance in
developing CTL based vaccines. Further, a CTL based HIV-1 vaccine is likely to have long-term
protective effect against disease only if the escape virus is significantly weakened compared with
wild type.
Data on humans infected with human immunodeficiency
virus type 1 (HIV-1) and macaques infected with simian
immunodeficiency virus (SIV) suggest that cytotoxic T-
lymphocytes (CTL) are important in controlling virus rep-
lication [1]. CTL target infected cells by recognizing viral
peptides (8–10 residues in length) bound to class I major
histocompatibility complex (MHC) molecules. Different
MHC alleles bind viral peptides with different affinities.
MHC alleles, which bind particular viral peptides well,
often result in strong cellular responses against those viral
epitopes. In theory, if CTL are important in controlling or
reducing HIV-1 replication in vivo, then virus mutants that
avoid this cellular response should have a replicative
advantage in the host. Indeed, several studies in both
macaques and humans have documented the presence of
virus mutants that escape the dominant CTL response and
become the major replicating strain in vivo [2,3]. In most
examples to date, the mutant or escape virus replicates
efficiently and viral loads remain considerable. However,
the impact of CTL escape mutations on viral fitness has
not been extensively examined.
Recently, two groups addressed whether CTL escape
mutants are virologically less fit than their wild type coun-
terparts [4,5]. In side-by-side papers published in the
March 2004 issue of Nature Medicine, Friedrich et al. [4]
examined SIV in the macaque model, while Leslie et al. [5]
studied HIV-1 in human mother-infant pairs. In the SIV/
macaque model, earlier reports have established three dis-
crete CTL escape epitopes associated with two MHC class
alleles [6]. Two of these epitopes, located in Gag and Tat,
respectively, are bound by Mamu-A*01, while the third
epitope, located in Nef, binds Mamu-B*17. In rhesus
macaques with the cognate class I alleles, each of these
epitopes is seen at high frequency following infection
with SIVmac239 [6]. None is seen in SIVmac239-infected
macaques that lack Mamu-A*01 or Mamu-B*17 alleles.
Studies by Friedrich and colleagues demonstrated that in
vitro replication of SIVmac239 encoding escape epitopes
in Gag, Tat, and Nef (termed 3x SIV) is impaired com-
pared to wild type virus [4], suggesting a relatively lower
level of fitness. Infection of two rhesus macaques negative
for either Mamu-A*01 or Mamu-B*17 also yielded inter-
esting results. In the first four weeks after infection with 3x
SIV, mutations in all three, escape epitopes were main-
tained. By week 16 the Gag mutant had reverted towards
wild type and by week 20 the Nef mutations had also
reverted. The Tat peptide did not revert. During these 20
weeks, the viral loads of these animals did not change
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appreciably. However, these reversions to wild type after 4
to 5 months of infection strongly suggest that these CTL
escape mutants are less fit in vivo than wild type viruses in
the absence of immune pressure.
Similar conclusions were reached in analyses of HIV-1 ver-
tical transmission in mother-infant pairs, in which spe-
cific Class I alleles are not shared [5]. In HIV-1 infection of
humans, two closely related HLA molecules, B57 and
B5801, are associated with relative control of virus repli-
cation [7-10]. The dominant CTL response associated
with HLA-B57 positive individuals is against a Gag pep-
tide, TW10. Significant variation in this peptide is seen
after HIV-1 transmission from HLA-B57/B5801 negative
individuals to those who carry either allele, although not
all clinical progressors, who carry HLA-B57, have virus
with escape mutations in TW10 [11]. Analysis of two
mother-infant pairs after vertical transmission of HIV-1
revealed that the mothers, who were each HLA-B57/B508
positive, had CTL escape mutations in TW10. The two
infants, each negative for HLA B57/B508, were initially
infected with virus carrying these mutations. However,
over the ensuing months, the escape mutations in TW10
reverted to wild type in both infants. Taken together, these
results strongly support the idea that at least some CTL
escape mutations come at a cost to overall viral fitness,
and this cost may be enough to prevent any lasting impact
on overall viral evolution.
In a recent study of SIV pathogenesis, we observed similar,
striking results for CTL escape mutants [12]. To evaluate
the role of the second coding exon of Tat in vivo, we engi-
neered a mutant of SIVmac239 with dual stop codons at
the end of the first exon of Tat (SIVtat1ex). These stop
codons had no effect on virus replication in vitro and
resulted in minor amino acid changes in Rev that did not
affect its function. Comparison of four rhesus macaques
(L840, L855, L882, N200) infected with SIVtat1ex with
control macaques infected with wild type SIVmac239
showed no differences in viral load or CD4+ T-cell counts
during acute infection. Subsequently, we observed that
two of the macaques infected with SIVtat1ex (L840, L855)
completely controlled viremia, while two (L882, N200)
had appreciable viral loads. Three months after infection,
we examined the stop codons at the end of the first exon
of Tat. In one of the animals with persistent viremia
(L882), the virus had mutated the stop codons to encode
the second exon of Tat. This animal had a very high viral
load and low CD4+ T-cell counts. Nine months post-infec-
tion (p.i.) it became ill with simian AIDS and was
euthanized.
Analysis of viruses from the other three macaques indi-
cated that the stop codons in Tat remained intact for 8
months p.i. At this time, the tat reading frame from one of
these animals (L840) opened up and this reversion was
associated with a decrease in CD4+ T-cell counts and a
modest increase in viral load. However, at day 548 p.i., the
stop codons in tat's first exon re-emerged and this rever-
sion was coincident with an increase in CD4+ T-cell counts
and a reduction in viral load to undetectable levels. The
stop codons at the end of the first exon of tat persisted for
four years and this animal remains healthy.
Viruses from the other macaque that initially controlled
viremia (L855) maintained the stop codons in tat's first
exon for over one year p.i. However, between days 413–
485 p.i., the viral load in this animal increased from unde-
tectable to ~105 copies/ml. Analysis of virus during this
period revealed that the stop codons in tat had opened up
and the virus now encoded both exons of Tat. The CD4+
T-cell count, which had been stable in this animal, began
to steadily decrease and its viral load increased to 106 cop-
ies/ml. The stop codons in tat's first exon did not re-
emerge. This animal eventually developed simian AIDS
and was euthanized.
We next sought to determine why virus from one infected
macaque (L840) transiently opened up the stop codons in
tat, whereas viruses from two other infected macaques
(L882 and L855) permanently reverted to encode both Tat
exons. Western blot analysis showed similar anti-SIV anti-
body responses in L840 and L855 (L882 had only a weak
antibody response). Using a γ-interferon ELISpot assay,
we found that L840 had a much stronger cellular response
against Tat second exon peptides than L882 or L855.
These data, taken together, suggest the following:
1. SIV encoding two-exon Tat is more fit than SIVtat1ex in
vivo.
2. Reversion from SIVtat1ex to SIV encoding two-exon Tat
is associated with increased viral loads and decreased
CD4+ T-cell counts.
3. In L882 and L855, a limited CTL response specific for
the second exon of Tat developed and when the virus
reverted, little immune pressure was placed on the new
virus. On the other hand, L840 mounted a strong CTL
response against epitopes in the second exon of Tat. The
immune selection favored the re-emergence of SIVtat1ex
as the predominant virus.
4. In the absence of immune pressure, SIV encoding two-
exon Tat is more fit than SIVtat1ex (Figure 1), but in the
setting of strong immunologic pressure, SIVtat1ex is more
fit, albeit less pathogenic (Figure 2).
Curiously, virus from macaque L840 evaded Tat second
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by simple amino acid mutations within the epitope. As in
the papers described above, most HIV/SIV escape mutants
have 2 to 3 amino acid changes in the dominant epitope
[3]. Presumably, amino acid escape mutations in the Tat
second exon epitope(s), targeted in L840, resulted in a
substantial decrease in viral fitness. To our knowledge,
this observation is unique in the HIV/SIV CTL literature.
The second exon of tat is overlapped completely by rev
and env and, as a consequence, any nucleic acid mutation
in this region affects all three genes. Perhaps the necessity
of maintaining these overlapping reading frames con-
strained the ability of Tat to sustain point mutations in the
second exon and prevented escape from CTL.
Many current vaccine strategies for HIV and SIV in the
non-human primate model are CTL-based (reviewed in
[13,14]). Given what is known about CTL, it is probable
that HIV and SIV can evade any specific CTL clone or
clones. The purpose of a CTL-based vaccine against HIV-1
is, therefore, not to prevent viral escape but rather to force
the virus to mutate to a less fit phenotype. We are cur-
rently studying this hypothesis by evaluating CTL against
Rev, Tat and Env in the SIV/macaque model. By inducing
immune responses against these overlapping regions, we
hope to demonstrate that mutations associated with CTL
escape will result in a virus that is significantly less patho-
genic than wild type. In almost all cases, changing a base
Cartoon representation of SIVtat1ex fitness in vivo Figure 1
Cartoon representation of SIVtat1ex fitness in vivo. In the absence of CTL against Tat second exon epitopes (Tat 2 ex), SIV 
encoding two-exon Tat are more fit and replicate to higher levels. The single exon Tat genome is represented by a pink bar 
with a jagged edge; the two-exon Tat genome is depicted by a green rectangle. Viruses are illustrated as hexagons with inner 
ovals.
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pair in this region of HIV or SIV changes the encoded
amino acid in at least two reading frames. For example,
changing the nucleotide in the first position of any tat sec-
ond exon codon also changes the translation of the over-
lapping env  codon. Consistent with this approach, the
goal of all CTL-based vaccine strategies should not only be
to raise significant cellular responses against viral
epitopes, but also to choose epitopes of which mutation
results in a significant decrease in viral fitness. Thus far,
encouraging results in our and these recent studies [4,5]
suggest this may be possible; however, determining which
epitopes have these properties is an empirically difficult
task.
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